Pimecrolimus | Interleukin Related interleukin-related.com

Product Name :
Pimecrolimus

Search keywords :
PAR

drugId :
null

Target Vo:
FK506 binding protein

Target Vo Short Name :
FKBP

Moa_Name:
FK506 binding protein modulators

First Approval Country :
United States

First Approval Date Filter:
2001

Origin Company_Name :
Novartis Pharma Ag

Active Company_Name :
Bausch & Lomb (Singapore) Pvi Ltd

Active Indication_Name:
Eczema

In Active Indication_Name:
Netherton Syndrome

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
DXd Antibody (YA897)
Phospho-Rb (Ser807) Antibody
LC3B Antibody: LC3B Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 15 kDa, targeting to LC3B. It can be used for WB,ICC/IF,IHC-F,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts